MedPath

Phase II multicenter randomized trial evaluating the association of PIPAC and systemicchemotherapy versus systemic chemotherapy alone as 1st-line treatment of MalignantPeritoneal Mesothelioma

Phase 1
Active, not recruiting
Conditions
Malignant Peritoneal Mesothelioma
MedDRA version: 21.0Level: LLTClassification code: 10034670Term: Peritoneal mesothelioma malignant localised Class: 10029104
MedDRA version: 21.0Level: LLTClassification code: 10034669Term: Peritoneal mesothelioma malignant advanced Class: 10029104
Therapeutic area: Diseases [C] - Neoplasms [C04]
Registration Number
CTIS2024-515343-39-00
Lead Sponsor
Institut Regional Du Cancer De Montpellier
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Recruiting
Sex
All
Target Recruitment
66
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: ;Secondary Objective: ;Primary end point(s):
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath